Follicular lymphoma: first - line selection criteria of treatment
- 作者: Nesterova E1, Kravchenko S1, Kovrigina A1, Gemdzhian E1, Plastinina L1, Babaeva F1, Obukhova T1, Magomedova A1, Gaponova T1, Kremenetskaya A1, Vorobyev A1
-
隶属关系:
- National Research Center for Hematology
- 期: 卷 91, 编号 8 (2019)
- 页面: 75-83
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/33627
- DOI: https://doi.org/10.26442/00403660.2019.08.000388
- ID: 33627
如何引用文章
全文:
详细
作者简介
E Nesterova
National Research Center for Hematology
Email: nest.ek@yandex.ru
к.м.н., н.с., врач-гематолог отд-ния интенсивной высокодозной химиотерапии гемобластозов с дневным и круглосуточным стационаром Moscow, Russia
S Kravchenko
National Research Center for Hematologyк.м.н., зав. отд-нием интенсивной высокодозной химиотерапии гемобластозов с дневным и круглосуточным стационаром Moscow, Russia
A Kovrigina
National Research Center for Hematologyд.б.н., зав. патологоанатомическим отд-нием Moscow, Russia
E Gemdzhian
National Research Center for Hematologyс.н.с. лаб. биостатистики; ORCID: 0000-0002-8357-977x Moscow, Russia
L Plastinina
National Research Center for Hematologyк.м.н., врач консультативно-гематологического отд-ния с дневным стационаром по проведению интенсивной высокодозной химиотерапии Moscow, Russia
F Babaeva
National Research Center for Hematologyаспирант отд-ния интенсивной высокодозной химиотерапии гемобластозов с дневным и круглосуточным стационаром Moscow, Russia
T Obukhova
National Research Center for Hematologyк.м.н., зав. лаб. кариологии Moscow, Russia
A Magomedova
National Research Center for Hematologyд.м.н., в.н.с. отд-ния интенсивной высокодозной химиотерапии гемобластозов с дневным и круглосуточным стационаром Moscow, Russia
T Gaponova
National Research Center for Hematologyк.м.н., зам. ген. директора по трансфузиологии, зав. отд. процессинга клеток крови и криоконсервирования Moscow, Russia
A Kremenetskaya
National Research Center for Hematologyзав. отд-нием интенсивной высокодозной химиотерапии гемобластозов с дневным и круглосуточным стационаром Moscow, Russia
A Vorobyev
National Research Center for Hematologyакадемик РАН, рук. отд-ния химиотерапии и интенсивной терапии гематологических заболеваний Moscow, Russia
参考
- Swerdlow S.H, Swerdlow S, Campo E, Harris N, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. World Health Organization, 2017; Vol. 2.
- Anastasia A, Rossi G. Novel Drugs in Follicular Lymphoma. Mediterr J Hematol Infect Dis. 2016;8(1):e2016061. doi: 10.4084/MJHID.2016.061
- Cheah C.Y, Fowler N.H. Novel agents for relapsed and refractory follicular lymphoma. Best Pract Res Clin Haematol. 2018;31(1):41-8. doi: 10.1016/j.beha.2017.11.003
- Dreyling M, Ghielmini M, Rule S, Salles G, Vitolo U, Ladetto M; ESMO Guidelines Committee. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow - up. Ann Oncol. 2016;27(Suppl 5):v83-90. doi: 10.1093/annonc/mdx020
- Поддубная И.В., Савченко В.Г., редакторы. Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. М., 2018.
- NCCN 2018-2019 oncology case manager and medical director program: diagnosis and management of hematologic malignancies. Version 2.2018. 2018 Jan 19.
- Mondello P, Steiner N, Willenbacher W, Wasle I, Zaja F, Zambello R, et al. Bendamustine plus rituximab versus R-CHOP as first - line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study. Ann Hematol. 2016;95(7):1107-14. doi: 10.1007/s00277-016-2668-0. Epub 2016 Apr 22.
- Luminari S, Goldaniga M, Cesaretti M, Orsucci L, Tucci A, Pulsoni A, et al. A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non - follicular non-Hodgkin lymphoma. Leuk Lymphoma. 2016;57(4):880-7. doi: 10.3109/10428194.2015.1091934. Epub 2016 Feb 8.
- Mondello P, Steiner N, Willenbacher W, Cerchione C, Nappi D, Mauro E, Ferrero S, Cuzzocrea S, Mian M. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study. Oncologist. 2018 Apr;23(4):454-60. doi: 10.1634/theoncologist.2017-0037. Epub 2018 Jan 9.
- Rummel M.J, Niederle N, Maschmeyer G, Banat G.A, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W; Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first - line treatment for patients with indolent and mantle - cell lymphomas: an open - label, multicentre, randomised, phase 3 non - inferiority trial. Lancet. 2013 Apr 6;381(9873):1203-10. doi: 10.1016/S0140-6736(12)61763-2. Epub 2013 Feb 20.
- Morschhauser F, Seymour J, Feugier P, Offner F, Lopez-Guillermo A, Bouabdallah R, Pedersen L, et al. Impact of induction chemotherapy regimen on response, safety and outcome in the PRIMA study. Ann Oncol. 2011;22:89-9. Presented at the 11th International conference on Malignant Lymphoma. doi: 10.1007/978-1-62703-408-19
- Yamaguchi T, Morita T, Takahashi Y, Tsuda K, Mori J. Treatment for patients with indolent and mantle cell lymphoma. Lancet. 2013 Sep 28;382(9898):1094-5. doi: 10.1016/S0140-6736(13)62018-8
- Morrison V.A, Shou Y, Bell J.A, Hamilton L, Ogbonnaya A, Raju A, Hennenfent K, Eaddy M, Galaznik A. Treatment Patterns and Survival Outcomes in Patients With Follicular Lymphoma: A 2007 to 2015 Humedica Database Study. Clin Lymphoma Myeloma Leuk. 2019 Jan 2. pii: S2152-2650(18)31126-1. doi: 10.1016/j.clml.2018.12.017
- Нестерова Е.С., Кравченко С.К., Ковригина А.М. и др. Фолликулярная лимфома: результаты многоцентрового исследования терапии первой линии препаратами бендамустин и ритуксимаб; факторы риска неблагоприятных событий (протокол FL-RUS-2013). Онкогематология. 2018;13(3):10-24. doi: 10.17650/1818-8346-2018-13-3-10-24
- Нестерова Е.С., Кравченко С.К., Барях Е.А. и др. Tрансплантация аутологичных стволовых клеток крови в первой ремиссии фолликулярной лимфомы как «терапия спасения» пациентов с факторами неблагоприятного прогноза. Результаты первого проспективного исследования. Современная онкология. 2016;18(5):31-2.
- Нестерова Е.С., Кравченко С.К., Мангасарова Я.К. и др. Фолликулярная лимфома. Высокодозная иммунохимиотерапия с трансплантацией аутологичных стволовых клеток крови: результаты первого проспективного исследования в России. Терапевтический архив. 2016;88(7):62-71. doi: 10.17116/terarkh201688762-71
- Wahlin B.E, Yri O.E, Kimby E, et al. Clinical significance of the WHO grades of follicular lymphoma in a population - based cohort of 505 patients with long follow - up times. Br J Haematol. 2012;156 (2):225-33. doi: 10.1111/j.1365-2141.2011.08942.x. Epub 2011 Nov 30.
- Senaras C, Pennell M, Chen W, Shana'ah A, Louissaint A, Hasserjian R.P, Lozanski G, Gurcan M.N. FOXP3-stained image analysis for follicular lymphoma: Optimal adaptive thresholding with maximal nucleus coverage. Proc SPIE Int Soc Opt Eng. 2017 Feb 11;10140. doi: 10.1117/12.2255671. Epub 2017 Mar 1.
- Laurent C, Müller S, Do C, Al-Saati T, Allart S, Larocca L.M, Hohaus S, Duchez S, Quillet-Mary A, Laurent G, Brousset P, Valitutti S. Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue - imaging study. Blood. 2011 Nov 17;118(20):5371-9. doi: 10.1182/blood-2011-04-345777. Epub 2011 Aug 19.
- Tarella C, Zanni M, Magni M, Benedetti F, Patti C, Barbui T, Pileri A, Boccadoro M, Ciceri F, Gallamini A, Cortelazzo S, Majolino I, Mirto S, Corradini P, Passera R, Pizzolo G, Gianni A.M, Rambaldi A. Rituximab improves the efficacy of high - dose chemotherapy with autograft for high - risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey. J Clin Oncol. 2008;26:3166-75. doi: 10.1200/JCO.2007.14.4204
- Buske C, Dreyling M. Malignant B-Cell Lymphoma: Advances in the Therapy of Follicular Lymphoma and Mantle - cell Lymphoma. Dtsch Med Wochenschr. 2018 Jan;143(1):46-51. doi: 10.1055/s-0043-124004. Epub 2018 Jan 9.
- Montoto S, Corradini P, Dreyling M, et al. Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma:a consensus project of the EBMT Lymphoma Working Party. Haematologica. 2013 Jul;98(7):1014-21.
- Cheson B.D, Fisher R.I, Barrington S.F, et al. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. J Clin Oncol. 2014;32(27):3059-68. doi: 10.1200/JCO.2013.54.8800
- Weiler-Sagie M, Buschelev O, Epelbaum R, et al. 18F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med. 2010;51:25-30. doi: 10.2967/jnumed.109.067892
- Tsukamoto N, Kojima N, Hasegawa M, et al. The usefulness of 18F-Fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET) and a comparison with 67Gallium scintigraphy in the evaluation of lymphoma. Cancer. 2007;110(3):652-9. doi: 10.1002/cncr.22807 PMID: 17582800
- Delfau-Larue M.H, van der Gucht A, Dupuis J, Jais J.P, Nel I, Beldi-Ferchiou A, Hamdane S, Benmaad I, Laboure G, Verret B, Haioun C, Copie-Bergman C, Berriolo-Riedinger A, Robert P, Casasnovas R.O, Itti E. Total metabolic tumor volume, circulating tumor cells, cell - free DNA: distinct prognostic value in follicular lymphoma. Blood Adv. 2018 Apr 10;2(7):807-16. doi: 10.1182/bloodadvances.2017015164
- Abou-Nassar K.E, Vanderplas A, Friedberg J.W, Abel G.A, Niland J, Rodriguez M.A, Czuczman M.S, Millenson M, Crosby A, Gordon L.I, Zelenetz A.D, Kaminski M, Lacasce A.S. Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database. Leuk Lymphoma. 2013 Oct;54(10):2155-62. doi: 10.3109/10428194.2013.770151. Epub 2013 Feb 25.
- Nesterova E.S, Kravchenko S.K, Baryakh E.A, et al. Autologous stem cell transplantation (AutoSCT) in first remission of follicular lymphoma (FL) “save“ patients (pts) with poor prognosis. results of the first Russian prospective study. Blood. 2015;126(23):5079.
- Nesterova E.S, Kravchenko S.K, Kovrigina A.M, et al. Front - line high dose therapy with following autologous stem cell transplantation (ASCT) for follicular lymphoma patients. Blood. 2014;124(21):5908.
- Нестерова Е.С., Кравченко С.К., Гемджян Э.Г. и др. Итоги десятилетнего опыта лечения больных фолликулярной лимфомой. Гематология и трансфузиология. 2012;57(5):3-8.